← Back to Search

FXR Agonist

2mg CS0159 for Non-alcoholic Fatty Liver Disease

Phase 2
Waitlist Available
Research Sponsored by Cascade Pharmaceuticals, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 6, week 12

Summary

This trial is testing a new drug called CS0159 to see if it can help people with a liver disease called NASH. The study will check if the drug is safe and if it can improve liver health by reducing inflammation and fat in the liver.

Eligible Conditions
  • Non-alcoholic Fatty Liver Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 6, week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 6, week 12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Adverse events
Magnetic Resonance Imaging
Secondary study objectives
AUC
Cmax
Pharmacodynamics (PD)
+2 more

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: 2mg CS0159Experimental Treatment1 Intervention
One tablet daily for 12 weeks
Group II: 1.4mg CS0159Experimental Treatment1 Intervention
One tablet daily for 12 weeks
Group III: PLACEBOPlacebo Group1 Intervention
One tablet daily for 12 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CS0159 (Linafexor)
2023
Completed Phase 2
~100

Find a Location

Who is running the clinical trial?

Cascade Pharmaceuticals, IncLead Sponsor
7 Previous Clinical Trials
406 Total Patients Enrolled
Laboratory Corporation of AmericaIndustry Sponsor
31 Previous Clinical Trials
18,604 Total Patients Enrolled
Rong DengStudy DirectorCascade Pharmaceuticals, Inc
2 Previous Clinical Trials
125 Total Patients Enrolled

Media Library

CS0159 (Linafexor) (FXR Agonist) Clinical Trial Eligibility Overview. Trial Name: NCT05591079 — Phase 2
Non-alcoholic Fatty Liver Disease Research Study Groups: 2mg CS0159, 1.4mg CS0159, PLACEBO
Non-alcoholic Fatty Liver Disease Clinical Trial 2023: CS0159 (Linafexor) Highlights & Side Effects. Trial Name: NCT05591079 — Phase 2
CS0159 (Linafexor) (FXR Agonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05591079 — Phase 2
~36 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top